In vitro discovery and optimization of a human monoclonal antibody that neutralizes neurotoxicity and lethality of cobra snake venom
Line LedsgaardiD, Andreas H. LaustseniD, Urška Puš, Jack WadeiD, Pedro Villar, Kim BoddumiD, Peter SlavnyiD, Edward W. Masters, Ana Silvia AriasiD, Saioa Oscoz, Daniel T. GriffithsiD, Alice M. LutheriD, Majken LindholmiD, Rachael A. Leah, Marie Sofie MølleriD, Hanif AliiD, John McCaffertyiD, Bruno LomonteiD, José Marı́a GutiérreziD, Aneesh Karatt-VellattiD
Abstract
The monocled cobra (Naja kaouthia) is one of the most feared snakes in Southeast Asia. It is a highly dangerous species with a potent venom deriving its toxicity predominantly from abundant long-chain -neurotoxins. The only specific treatment for snakebite envenoming is antivenom, which is based on animal-derived polyclonal antibodies. Despite the lifesaving importance of these medicines over the past 120 years, and their ongoing role in combating snakebite disease, major limitations in safety, supply consistency, and efficacy creates a need for a new generation of improved treatments based on modern biotechnological techniques. Here, we describe the initial discovery and subsequent optimization of a recombinant human monoclonal immunoglobin G (IgG) antibody against -cobratoxin using phage display technology. Affinity maturation of the parental antibody by light chain-shuffling resulted in an 8-fold increase in affinity, translating to a significant increase in in vitro neutralization potency and in vivo efficacy. While the parental antibody prolonged survival of mice challenged with purified -cobratoxin, the optimized antibody prevented lethality when incubated with N. kaouthia whole venom prior to intravenous injection. This study is the first to demonstrate neutralization of whole snake venom by a single recombinant monoclonal antibody. Importantly, this suggests that for venoms whose toxicity relies on a single predominant toxin group, such as that of N. kaouthia, as little as one monoclonal antibody may be sufficient to prevent lethality, thus providing a tantalizing prospect of bringing recombinant antivenoms based on human monoclonal or oligoclonal antibodies to the clinic. One Sentence SummaryA recombinant human monoclonal immunoglobulin G antibody, discovered and optimized using in vitro methods, was demonstrated to neutralize the lethal effect of whole venom from the monocled cobra in mice via abrogation of -neurotoxin-mediated neurotoxicity.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 4
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Discovery of a broadly-neutralizing human antibody that can rescue mice challenged with neurotoxin-rich snake venoms
L. Ledsgaard, J. Wade, … A. Karatt-Vellatt·bioRxiv·Jun 17, 2022
- Venom protection by broadly neutralizing antibody from a snakebite subject
J. Glanville, J. C. Andrade, … P. D. Kwong·bioRxiv·Sep 26, 2022
- De novo designed single-domain antibodies protect against lethal cobra venom neurotoxicity in vivo
Max D. Overath, Emil V. S. Lundquist, … Timothy P. Jenkins·bioRxiv·Sep 3, 2026
- Antibodies against Elapidae and Viperidae snake venoms: in vivo neutralization and mechanistic insights
A. Kumar, Z. K. Madni, … D. M. Salunke·bioRxiv·Jun 16, 2023
- Antigenic Divergence of Cobra Short-chain α-Neurotoxins: Implications for Regional Antivenom Effectiveness in Southeast Asia
Choo Hock Tan, Praneetha Palasuberniam, … Nget Hong Tan·PLoS neglected tropical diseasesPeer-reviewed·May 14, 2026
- Extremely potent human monoclonal antibodies for the prophylaxis and therapy of Tetanus
M. Pirazzini, A. Grinzato, … C. Montecucco·bioRxiv·May 24, 2021